Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;26(1):3-14.
doi: 10.1111/camh.12437. Epub 2020 Dec 15.

Review: Puberty blockers for transgender and gender diverse youth-a critical review of the literature

Lynn Rew  1 , Cara C Young  1 , Maria Monge  2 , Roxanne Bogucka  3
Affiliations

Review: Puberty blockers for transgender and gender diverse youth-a critical review of the literature

Lynn Rew et al. Child Adolesc Ment Health. 2021 Feb.

Abstract

Background: Increasingly, early adolescents who are transgender or gender diverse (TGD) are seeking gender-affirming healthcare services. Pediatric healthcare providers supported by professional guidelines are treating many of these children with gonadotropin-releasing hormone agonists (GnRHa), which reversibly block pubertal development, giving the child and their family more time in which to explore the possibility of medical transition.

Methods: We conducted a critical review of the literature to answer a series of questions about criteria for using puberty-blocking medications, the specific drugs used, the risks and adverse consequences and/or the positive outcomes associated with their use. We searched four databases: LGBT Life, PsycINFO, PubMed, and Web of Science. From an initial sample of 211 articles, we systematically reviewed 9 research studies that met inclusion/exclusion criteria.

Results: Studies reviewed had samples ranging from 1 to 192 (N = 543). The majority (71%) of participants in these studies required a diagnosis of gender dysphoria to qualify for puberty suppression and were administered medication during Tanner stages 2 through 4. Positive outcomes were decreased suicidality in adulthood, improved affect and psychological functioning, and improved social life. Adverse factors associated with use were changes in body composition, slow growth, decreased height velocity, decreased bone turnover, cost of drugs, and lack of insurance coverage. One study met all quality criteria and was judged 'excellent', five studies met the majority of quality criteria resulting in 'good' ratings, whereas three studies were judged fair and had serious risks of bias.

Conclusion: Given the potentially life-saving benefits of these medications for TGD youth, it is critical that rigorous longitudinal and mixed methods research be conducted that includes stakeholders and members of the gender diverse community with representative samples.

Keywords: Transgender; adolescent; critical review; puberty blockers.

PubMed Disclaimer

Comment in

References

    1. Achille, C., Taggart, T., Eaton, N.R., Osipoff, J., Tafuri, K., Lane, A., & Wilson, T.A. (2020). Longitudinal impact of gender-affirming endocrine intervention on the mental health and well-being of transgender youths: Preliminary results. International Journal of Pediatric Endocrinology, 8. https://doi.org/10.1186/s13633-020-00078-2
    1. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th edn). Arlington, VA: American Psychiatric Publishing.
    1. Ashley, F. (2019). Puberty blockers are necessary, but they don’t prevent homelessness: Caring for transgender youth by supporting unsupportive parents. The American Journal of Bioethics, 19, 87-89.
    1. Bonifacio, H.J., & Rosenthal, S.M. (2015). Gender variance and dysphoria in children and adolescents. Pediatric Clinics of North America, 62, 1001-1016.
    1. Campbell, D.T., & Stanley, J.C. (1963). Experimental and quasi-experimental designs for research. Boston: Houghton Mifflin Company.

Publication types

LinkOut - more resources